- Trials with a EudraCT protocol (227)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
227 result(s) found for: Psoriasis Area and Severity Index.
Displaying page 1 of 12.
EudraCT Number: 2013-003086-34 | Sponsor Protocol Number: CAIN457A3301 | Start Date*: 2013-12-04 | ||||||||||||||||
Sponsor Name:Novartis Pharma Services AG | ||||||||||||||||||
Full Title: A 52-week, multicenter, randomized, double-blind, placebo-controlled study of subcutaneous secukinumab to demonstrate efficacy as assessed by palmoplantar pustulosis Psoriasis Area and Severity Ind... | ||||||||||||||||||
Medical condition: Moderate to severe chronic palmoplantar pustular psoriasis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: SE (Completed) GB (Completed) AT (Completed) ES (Completed) DE (Completed) BE (Completed) IT (Completed) PL (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-000571-13 | Sponsor Protocol Number: VIC-PSO1 | Start Date*: 2011-05-24 | |||||||||||
Sponsor Name:Gentofte Hospital | |||||||||||||
Full Title: The effect of GLP-1 in psoriasis | |||||||||||||
Medical condition: Psoriasis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-005339-15 | Sponsor Protocol Number: CAIN457A3302 | Start Date*: 2015-05-29 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: Long term clear skin maintenance treatment optimization in patients with moderate to severe chronic plaque psoriasis: A randomized, multicenter, open-label with blinded-assessment, comparative, 52 ... | |||||||||||||
Medical condition: Plaque Psoriasis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PT (Completed) ES (Completed) IE (Completed) NL (Completed) CZ (Completed) SK (Completed) AT (Completed) BE (Completed) HU (Completed) SE (Completed) DE (Completed) BG (Completed) DK (Completed) FI (Completed) LV (Completed) LT (Completed) FR (Completed) GR (Completed) GB (Completed) PL (Completed) HR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002481-31 | Sponsor Protocol Number: IM011-011 | Start Date*: 2017-02-02 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 2 Study to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects with Moderate to Severe Psoriasis | |||||||||||||
Medical condition: Moderate to Severe Psoriasis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LV (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-014364-18 | Sponsor Protocol Number: 579/09 | Start Date*: 2009-10-01 | |||||||||||
Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI | |||||||||||||
Full Title: PSORIASIS AND CARDIOVASCULAR DISEASE: IMMUNOMODULATOR ROLE OF THE TREATMENT WITH ROSUVASTATIN IN PATIENTS WITH PSORIASIS OF MILD OR OF MODERATE-SEVERE SKIN DISEASE. | |||||||||||||
Medical condition: PSORIASIS | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-007011-24 | Sponsor Protocol Number: 1583 | Start Date*: 2007-09-21 | |||||||||||
Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI | |||||||||||||
Full Title: Assessment of endothelial function in patients with psoriasis before and after Etanercept treatment | |||||||||||||
Medical condition: moderate to severe psoriasis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-001891-31 | Sponsor Protocol Number: PS0010 | Start Date*: 2016-10-27 | |||||||||||
Sponsor Name:UCB Biopharma SPRL | |||||||||||||
Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose Ranging Study to Evaluate the Safety, Efficacy, Pharmacokinectics, and Pharmacodynamics of Bimekizumab in Adult sub... | |||||||||||||
Medical condition: Chronic Plaque Psoriasis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) CZ (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-001568-12 | Sponsor Protocol Number: 16-02/CalciBet-S | Start Date*: 2016-10-18 | |||||||||||||||||||||
Sponsor Name:Dermapharm AG | |||||||||||||||||||||||
Full Title: A multi-centre, randomised, double-blind, parallel-group phase III study to investigate the efficacy, safety, and tolerability of a generic calcipotriol-betamethasone ointment formulation compared ... | |||||||||||||||||||||||
Medical condition: chronic stable plaque psoriasis | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: BG (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2016-002368-15 | Sponsor Protocol Number: PS0016 | Start Date*: 2016-11-15 | |||||||||||
Sponsor Name:UCB Biopharma SPRL | |||||||||||||
Full Title: A Multicenter, Randomized, Subject-Blind, Investigator-Blind Study to Evaluate the Time Course of Pharmacodynamic Response, Safety and Pharmacokinetics of Bimekizumab in Adult Subjects With Moderat... | |||||||||||||
Medical condition: Chronic Plaque Psoriasis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-003287-37 | Sponsor Protocol Number: EMR200588-002 | Start Date*: 2016-03-15 | |||||||||||
Sponsor Name:Merck KGaA | |||||||||||||
Full Title: A randomized, double-blind, confirmatory trial to evaluate the efficacy, safety and immunogenicity of MSB11022 compared with European Union-Approved Humira® in subjects with moderate to severe chro... | |||||||||||||
Medical condition: moderate to severe plaque psoriasis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Completed) DE (Completed) GB (Completed) CZ (Completed) HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-000711-76 | Sponsor Protocol Number: N/A | Start Date*: 2020-07-13 | |||||||||||
Sponsor Name:Alexander Egeberg | |||||||||||||
Full Title: Efficacy of roflumilast in the treatment of psoriasis – a randomised controlled trial | |||||||||||||
Medical condition: Psoriasis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-002633-34 | Sponsor Protocol Number: ESK-001-006 | Start Date*: 2023-02-07 | |||||||||||
Sponsor Name:Alumis Inc. | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ESK-001 in Patients with Moderate to Severe Plaque Psoriasis | |||||||||||||
Medical condition: Moderate to Severe Plaque Psoriasis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) PL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-002532-24 | Sponsor Protocol Number: 0155/2018 | Start Date*: 2018-12-27 | |||||||||||
Sponsor Name:HELM AG | |||||||||||||
Full Title: A phase III, multicentre, randomised, double-blind, parallel-group trial to evaluate the efficacy and safety of a generic gel (calcipotriol + betamethasone 50 μg/g + 0.5 mg/g gel) compared to origi... | |||||||||||||
Medical condition: mild to moderate plaque-type psoriasis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-000892-28 | Sponsor Protocol Number: I1F-MC-RHBS | Start Date*: 2015-08-05 | |||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||
Full Title: Protocol I1F-MC-RHBS A 52-Week Multicenter, Randomized, Blinded, Parallel Group Study Comparing the Efficacy and Safety of Ixekizumab to Ustekinumab in Patients with Moderate to Severe Plaque Psor... | |||||||||||||
Medical condition: Moderate to severe plaque psoriasis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (Completed) SE (Completed) HU (Completed) NL (Completed) ES (Completed) AT (Completed) BE (Completed) PL (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-002446-36 | Sponsor Protocol Number: BP40635 | Start Date*: 2018-11-05 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||
Full Title: AN OPEN LABEL PHASE 2A TRIAL ASSESSING THE CLINICAL EFFICACY AND SAFETY OF RO5459072 IN MODERATE TO SEVERE PSORIASIS | |||||||||||||
Medical condition: Psoriasis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-005413-40 | Sponsor Protocol Number: CAIN457A2313 | Start Date*: 2013-04-25 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A randomized, double-blind, placebo-controlled, multicenter, study to demonstrate the efficacy at 16 weeks of secukinumab 150 and 300 mg s.c. and to assess safety, tolerability and longterm effi... | |||||||||||||
Medical condition: Moderate to severe nail psoriasis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) ES (Completed) BE (Completed) GR (Completed) DK (Completed) DE (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-002141-39 | Sponsor Protocol Number: CDP870-040 | Start Date*: 2005-10-25 | |||||||||||
Sponsor Name:UCB Pharma S.A. | |||||||||||||
Full Title: Multicenter, dose response, randomized, double blin, parallel, 3 arms, placebo controlled clinical trial to evaluate the efficacy and the safety of subcutaneous CDP870 (certolizumab pegol) at 2 dif... | |||||||||||||
Medical condition: Psoriasis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-001066-17 | Sponsor Protocol Number: CNTO1959PSO2001 | Start Date*: 2012-04-10 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Phase 2 Multicenter, Randomized, Placebo- and Active-Comparator-Controlled, Dose-Ranging Trial to Evaluate CNTO 1959 for the Treatment of Subjects with Moderate to Severe Plaque-type Psoriasis (X... | |||||||||||||
Medical condition: Moderate to Severe Plaque-type Psoriasis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-004230-42 | Sponsor Protocol Number: 18562 | Start Date*: 2020-07-31 | |||||||||||||||||||||
Sponsor Name:Radboudumc | |||||||||||||||||||||||
Full Title: Dose reduction of the new generation biologics (IL17 and IL23 inhibitors) in psoriasis: A pragmatic, multicentre, randomized, controlled, non-inferiority study - BeNeBio study | |||||||||||||||||||||||
Medical condition: psoriasis | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: BE (Completed) NL (Completed) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-002970-22 | Sponsor Protocol Number: I1F-MC-RHAZ(c) | Start Date*: 2012-05-31 | |||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||
Full Title: Protocol I1F-MC-RHAZ A Multicenter Study with a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Maintenance Dosing Period and a Long- Term Extensio... | |||||||||||||
Medical condition: Moderate to severe chronic plaque psoriasis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (Completed) HU (Completed) PL (Completed) IT (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
